JHOP - June 2016 Vol 6, No 2

Lack of sufficient vitamin B12 intake is often associated with the development of vitamin B12 deficiency anemia, which is a medical condition characterized by a low red blood cell count and vitamin B12.
The use of closed-system transfer devices (CSTDs) for compounding hazardous medications has become an accepted standard of practice to minimize environmental exposure to these agents.
From 2005 to 2014, the number of ongoing trials of chronic lymphocytic leukemia (CLL) has increased at a compound annual growth rate of 18.4%. This rapid growth in the CLL clinical trial landscape has led to multiple breakthroughs in the management of CLL, which have changed—and will continue to change—the treatment paradigm in the near future.
  • Personalizing Therapy for Patients with Multiple Myeloma
  • Targeting BCL2 with Venetoclax in Patients with Relapsed CLL

Results 1 - 4 of 4